NIH starts clinical trial testing antibody treatments in COVID-19 patients

The trial will test AbbVie Inc's psoriasis drug risankizumab along with Gilead Sciences' antiviral remdesivir, compared to a placebo and remdesivir. "The goal here is to identify as quickly as possible the experimental therapeutics that demonstrate the most clinical promise as COVID-19 treatments and move them into larger-scale testing," said NIAID Director and U.S. infectious diseases expert Anthony Fauci. Gilead's remdesivir, which was among the first to be used to treat COVID-19 and received emergency use authorization from the U.S. Food and Drug Administration in May, has since been authorized for use in several other countries.
Click here to read full news..